{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:36:47Z","timestamp":1790779007453,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jjcc.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T03:47:54Z","timestamp":1501904874000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["PCSK9 inhibition in the management of familial hypercholesterolemia"],"prefix":"10.1016","volume":"71","author":[{"given":"Masatsune","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2017.07.002_bib0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0140","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0145","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","article-title":"The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation","volume":"210","author":"Noguchi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2015.12.024","article-title":"Proprotein convertase subtilisin\/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia","volume":"10","author":"Ohta","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0155","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0160","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2006.12.035","article-title":"Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population","volume":"196","author":"Miyake","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0170","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0175","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.cb.01.110185.000245","article-title":"Receptor-mediated endocytosis: concepts emerging from the LDL receptor system","volume":"1","author":"Goldstein","year":"1985","journal-title":"Annu Rev Cell Biol"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0185","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0022-2275(20)35728-X","article-title":"Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans","volume":"34","author":"Dietschy","year":"1993","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0195","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0200","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0205","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0210","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0215","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0220","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1038\/mtna.2012.16","article-title":"Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0230","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0235","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","article-title":"Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 (PCSK9) by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9","volume":"100","author":"Hori","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0240","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"Le May","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0245","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.jjcc.2017.07.002_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","article-title":"Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages","volume":"256","author":"Adorni","year":"2017","journal-title":"Atherosclerosis"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508717301910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508717301910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:57:24Z","timestamp":1760273844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508717301910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0914508717301910"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2017.07.002","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 inhibition in the management of familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}